

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

TITLE

A facility and community-based assessment of scabies in rural Malawi

SHORT TITLE: Scabies control in Malawi

AUTHORS AND AFFILIATIONS

Cristina Galván-Casas^{1*}; Oriol Mitjá²; Sara Esteban-Terradillos³; Jacob Kafulafula⁴;
Texon Phiri⁵; Íñigo Navarro-Fernández⁶; Concepción Román-Curto⁷; Hassani Mtenje⁸;
Gerald Thauzeni⁹; Elizabeth Harawa¹⁰; Stephano Kaluzi¹¹; Mphatso Diere¹²; Mary
Mkandawire¹³; Shaibu Malizani¹⁴; Alex Chifundo¹⁵; Marta Utrera-Busquets¹⁶; Mónica
Roncero-Riesco¹⁷; Sara López Martín-Prieto¹⁸; Iosune Vilanova-Urdániz¹⁹; Gisela H.
Petiti²⁰; María Victoria de Gálvez Aranda²¹; Nuria No Pérez²²; María Rueda Gómez-
Calcerrada²³; Pilar Iranzo²⁴; Pilar Escalonilla García-Patos²⁵; Magdalena de Troya-
Martín²⁶; Javier Romero Gomez²⁷; Esther Cardeñoso-Alvarez²⁸; Sofia Lucas Truyols²⁹;
Libe Aspe Unanue³⁰; Cristina Bajo del Pozo³¹; Alicia Comunión Artieda³²; Maria Isabel
Martínez González³³; Omar F López-López³⁴; Esther Moreno-Artero³⁵; Xavier Cubiró³⁶;
Iago Meilán-Sánchez³⁷; Alejandra Tomás-Velázquez³⁸; Cristina López-Sánchez³⁹; Eva
M Sánchez-Martínez⁴⁰; Harrison A Edwards⁴¹; Maria Herrera Morueco⁴²; Julia Zehe
Rubiera⁴³; Laura Salguero Caldera⁴⁴; Urbano Blanes-Moreno⁴⁵; Maria Uribarren-
Movilla⁴⁶; Michael Marks⁴⁷

¹ Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.
Department of Dermatology. Hospital Universitario de Mostoles, Madrid, Spain.
DerMalawi Project, Nkhotakota, Malawi.

² Fight AIDS and Infectious Diseases Foundation, Badalona, Spain. Hospital Universitari
Germans Trias i Pujol, Badalona Spain. Lihir Medical Centre-International SOS, Lihir

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 27 ³ Department of Dermatology. Hospital Universitario de Cruces, Bilbao, Bizkaia, Spain.
- 28 ⁴ Chief Medical Office. Nkhotakota District Hospital. Malawi.
- 29 ⁵ Community programs manager. Alinafe Health Center. Malawi
- 30 ⁶ Department of Dermatology. Hospital Universitario de Cabueñes. Gijón. Spain.
- 31 ⁷ Department of Dermatology. Complejo Hospitalario Universitario de Salamanca. Spain.
- 32 ⁸ Health Surveillance Assistant. Alinafe Health Center. Nkhotakota. Malawi
- 33 ⁹ Health Surveillance Assistant. Mwansambo Health Center. Nkhotakota. Malawi
- 34 ¹⁰ Health Surveillance Assistant. Kapiri. Nkhotakota. Malawi
- 35 ¹¹ Health Surveillance Assistant. Benga Health Center. Nkhotakota. Malawi
- 36 ¹² Health Surveillance Assistant. Thavite Health Center. Salima. Malawi
- 37 ¹³ Data Clerk. Alinafe Health Center. Nkhotakota. Malawi
- 38 ¹⁴ Data Clerk. Alinafe Health Center. Nkhotakota. Malawi
- 39 ¹⁵ Counselor. Alinafe Health Center. Nkhotakota. Malawi
- 40 ¹⁶ Department of Dermatology. Hospital General La Mancha Centro. Ciudad Real. Spain.
- 41 ¹⁷ Department of Dermatology. Complejo Asistencial Universitario de Salamanca. Spain.
- 42 ¹⁸ Department of Dermatology. Hospital Virgen del Rocio. Sevilla. Spain.
- 43 ¹⁹ Department of Dermatology. Hospital General Universitario de Elche. Alicante. Spain.
- 44 ²⁰ Department of Dermatology. Hospital Mòisses Broggi. Barcelona. Spain.
- 45 ²¹ Department of Dermatology. Faculty of Medicine. Universidad de Málaga. Spain
- 46 ²² Department of Dermatology. Complejo hospitalario Universitario de Vigo. Spain.
- 47 ²³ Department of Dermatology. Hospital Viamed Virgen de la Paloma. Madrid. Spain.
- 48 ²⁴ Department of Dermatology. Hospital Clínic. Barcelona. Spain.

- 49 ²⁵ Department of Dermatology. Complejo Asistencial de Ávila. Spain.
- 50 ²⁶ Department of Dermatology. Hospital Costa del Sol. Marbella. Spain.
- 51 ²⁷ Department of Dermatology. Hospital Quironsalud. Málaga. Spain.
- 52 ²⁸ Department of Dermatology. Complejo Asistencial Universitario de Salamanca. Spain.
- 53 ²⁹ Department of Dermatology. Consorci Hospital General Universitari de València.
- 54 Spain.
- 55 ³⁰ Department of Dermatology. Hospital Universitario Araba. Vitoria-Gasteiz. Spain.
- 56 ³¹ Department of Dermatology. Complejo Hospitalario de Palencia. Spain
- 57 ³² Department of Dermatology. Centro de Diagnóstico Médico. Ayuntamiento de Madrid.
- 58 Spain.
- 59 ³³ Department of Dermatology. Hospital Universitario Araba. Vitoria-Gasteiz. Spain.
- 60 ³⁴ Department of Dermatology. Complejo Hospitalario Universitario A Coruña. Spain.
- 61 ³⁵ Department of Dermatology. Clínica Universidad de Navarra. Madrid. Spain.
- 62 ³⁶ Department of Dermatology. Hospital de la Santa Creu i Sant Pau, Barcelona. Spain.
- 63 ³⁷ Department of Dermatology. Complejo Hospitalario Universitario A Coruña. Spain.
- 64 ³⁸ Department of Dermatology. Clínica Universidad de Navarra. Pamplona. Spain.
- 65 ³⁹ Department of Dermatology. Hospital de la Santa Creu i Sant Pau, Barcelona. Spain.
- 66 ⁴⁰ Department of Dermatology. Hospital Universitario Doctor Peset. Valencia. Spain.
- 67 ⁴¹ Princess Alexandra Hospital. School of Public Health, University of Queensland.
- 68 Dermatology Research Centre, University of Queensland Diamantina Institute. Brisbane.
- 69 Australia
- 70 ⁴² Medicine Department. Hospital Universitario Infanta Leonor. Madrid. Spain.
- 71 ⁴³ Hospital Plató. Barcelona. Spain.

72 ⁴⁴ Hospital Universitario Germans Trias y Pujol. Barcelona. Spain.

73 ⁴⁵ Francisco de Vitoria University. Madrid. Spain

74 ⁴⁶ Alcalá University. Madrid. Spain

75 ⁴⁷ Clinical Research Department, Faculty of Infectious and Tropical Diseases, London

76 School of Hygiene & Tropical Medicine, London, United Kingdom

77 ***Corresponding author:**

78 **E-mail:** galvancasascristina@gmail.com

79 <https://orcid.org/0000-0002-9662-9537>

80

81

82

83 **ABSTRACT**

84 **Background:**

85 Scabies is a neglected tropical disease of the skin, causing severe itching, stigmatizing
86 skin lesions and systemic complications. Since 2015, the DerMalawi project provides an
87 integrated skin diseases clinics and Tele-dermatology care in Malawi. Clinic-based data
88 suggested a progressive increase in scabies cases observed. To better identify and treat
89 individuals with scabies in the region, we shifted from a clinic-based model to a
90 community-based outreach programme.

91 **Methods:**

92 From May 2015, DerMalawi project provide integrated skin diseases and Tele-
93 dermatological care in the Nkhotakota and Salima health districts in Malawi.
94 Demographic and clinical data of all patients personally attended are recorded. Due to a

95 progressive increase in the number of cases of scabies the project shifted to a
96 community-based outreach programme.

97 For the community outreach activities, we conducted three visits between 2018 to 2019
98 and undertook screening in schools and villages of Alinafe Hospital catchment area.
99 Treatment was offered for all the cases and school or household contacts.

100 **Results:** Scabies increased from 2.9% to 39.2% of all cases seen by the DerMalawi
101 project at clinics between 2015 to 2018. During the community-based activities
102 approximately 50% of the population was assessed in each of three visits. The
103 prevalence of scabies was similar in the first two rounds, 15.4% (2392) at the first visit
104 and 17.2% at the second visit. The prevalence of scabies appeared to be lower (2.4%)
105 at the third visit. The prevalence of impetigo appeared unchanged and was 6.7% at the
106 first visit and 5.2% at the final visit.

107 **Conclusions:** Prevalence of scabies in our study setting was very high suggesting that
108 scabies is a major public health problem in parts of Malawi. Further work is required to
109 more accurately assess the burden of disease and develop appropriate public health
110 strategies for its control.

111

112

113 **PLAIN ENGLISH SUMMARY:**

114 Scabies is an infestation of the skin caused by a mite. There is limited data on how
115 common scabies is in sub-Saharan Africa, including Malawi. The DerMalawi project has
116 been providing care for dermatological conditions in rural Malawi since 2015. Between
117 2015 and 2018 we observed an increase in patients with scabies attending for treatment.
118 In response, the project shifted from providing care at clinics to an approach using
119 community-based outreach.

120 Between 2018 and 2019 we conducted community-based activities on three occasions
121 in an area of approximately 30,000 individuals. The DerMalawi team visited schools
122 and villages to identify and treat cases of scabies and their contacts. We were able to
123 examine about 50% of the population on each visit.

124 Initially a large proportion of the population had scabies (15%) and this was similar
125 during our second community survey. At our third survey this appeared to have
126 decreased to 2% but it is difficult for us to know if this is because of treatment given in
127 the previous rounds.

128 Scabies is a major problem in rural populations in Malawi and public health strategies
129 are needed to reduce the disease burden.

130

131 **Keywords:** Scabies. Impetigo. Active case detection. Ivermectin (IVM). Permethrin
132 (PMT).

133

134 **Background:**

135 Scabies is a skin disease caused by infestation with the mite, *Sarcoptes scabiei* var.
136 *Hominis*. Human transmission is predominantly via skin-to-skin contact. Around 200-300
137 million people are affected each year [1,2], particularly among poor populations living in

138 crowded conditions in tropical areas. There are limited data on the epidemiology of
139 scabies in sub-Saharan Africa and in particular limited population level estimates of
140 disease prevalence.

141 Permethrin 5% topical ointment is widely considered the first line drug for treatment of
142 individuals with scabies [3] but there is increasing evidence that community wide
143 treatment with ivermectin is the best strategy for control in highly endemic areas. The
144 major challenge to the use of ivermectin is the current recommendation for two
145 separated doses and its relative contraindication in pregnant and breastfeeding women
146 and children under five years of age.[4–9].

147 Standard guidelines for scabies control are based on treatment of cases and contacts
148 [10], but this approach is not effective in highly-endemic areas [11] [12,13] . Different
149 mass treatment approaches have resulted in positive outcomes [14–16] Mass drug
150 administration of ivermectin as part of lymphatic filariasis control in Zanzibar was
151 associated with a 68% decrease of scabies treatment's prescription [17]. The first
152 comparative trial of mass drug administration for scabies was the Skin Health
153 Intervention Fiji Trial (SHIFT) which found that ivermectin-based mass drug
154 administration decreased the prevalence of scabies by 94% one year after the
155 intervention, and was superior to both mass drug administration of topical permethrin
156 and standard care [18].

157 Better data is needed on the epidemiology of scabies in sub-Saharan Africa. We report
158 both facility based and community-based data on scabies in rural Malawi, collected as
159 part of the DerMalawi project.

160

161

162 **Methods**

163 **Ethics Statement**

164 Data reported were routinely collected as part of the activities of the DerMalawi project.
165 The DerMalawi project was established in May 2015 to provide free, integrated skin
166 diseases care and Tele-dermatological consultations to communities in the Nkhotakota
167 and Salima health districts in Malawi. The DerMalawi project is governed by a
168 memorandum of understanding between a group of Spanish dermatologists and the
169 Malawian Health authorities with approval for all activities in the district granted by the
170 Nkhotakota health authorities. Patients give verbal consent when attending the
171 DerMalawi project for an assessment of their skin problems. Approval from the Malawi
172 Medical Council and District Hospital for the DerMalawi project are available in
173 supporting information.

174 **Clinic-Based Data Collection**

175 Since the beginning of the DerMalawi project, the demographic and clinical data of all
176 patients personally attended are recorded in spreadsheets, using tablets. Among the
177 clinical data we collected personal and family history, symptoms, dermatological
178 examination, complementary examinations performed, coded diagnosis (ICD-10) and
179 prescribed and administered treatment. This data included basic information on the
180 number of individuals assessed and the number of cases of major common skin
181 conditions including scabies, leprosy, fungal infections, ulcers, albinism and skin cancer.
182 During the period between May 2015 to March 2018, clinic-based data suggested that
183 there had been a progressive increase in the proportion and absolute number of cases
184 of scabies that we observed. In response to this observed increase in scabies cases, the
185 DerMalawi project in collaboration with the Malawi health and educational authorities
186 agreed to shift from a clinic-based model to a community-based outreach programme to
187 try and better identify and treat individuals with scabies in the region.

188

189 Community Based-Data Collection

190 The community outreach activities took place in the Alinafe Health Center catchment
191 area, Nkhotakota and Salima districts, Malawi, which has a population of approximately
192 30,000 individuals. The area has 14 schools, 94 villages and five health facilities. For the
193 purpose of project implementation, the zone was divided into basic units of action,
194 formed by schools and the villages related to each school center. Community
195 dermatology outreach activities were conducted in both schools and communities. Data
196 for the community outreach activities were collected at a community level during the
197 delivery of an active case search and treatment programme in schools and villages of
198 Alinafe Hospital catchment area from July 2018 through April 2019. The programme was
199 conducted in three rounds three and six months apart in July 2018, Oct 2018 and April
200 2019.

201 Outreach activities were administered to the population of 14 schools and 94 villages on
202 catch-all basis in a subsection of the catchment area normally covered by the DerMalawi
203 clinic-based service. Clinical teams visited the schools, class by class, and in villages
204 attempted to go house by house trying to reach all individuals present at the school or at
205 home. The teams combined Spanish dermatologists, staff from Alinafe Hospital, trained
206 Chichewa-English translators, community health managers and a local guide. Groups
207 were composed by enough males and females to ensure confidentiality during the skin
208 exam of individuals of both sexes. A week before each round we conducted health
209 awareness in the communities to educate the public to the program's aims through health
210 educators who disseminated information about scabies at community meetings, school
211 meetings and through public notices, pamphlets and posters in cooperation with village
212 leaders. As with our clinic-based data collection we collected based information on the
213 number of individuals seen, demographics but focused clinical examination on scabies
214 and impetigo in view of the marked increase we had seen at the health facility.

215

216 Examination:

217 In both clinic and community settings a dermatologist carried out a standardized whole
218 skin examination (including genitalia and buttocks – using tents to ensure).
219 Determination of scabies intensity was based on the number of lesions in categories of
220 mild (≤ 10), moderate (11 to 49), and severe (≥ 50).

221

222 Treatment:

223 At both the clinic and in the community, all individuals diagnosed of scabies were offered
224 one dose of oral ivermectin (200 μg per kilogram of body weight), which was taken under
225 the direct observation of study staff. Ivermectin was replaced with topical permethrin
226 cream in the following participants: children who weighed less than 15 kg, women who
227 were pregnant or breast-feeding. For participants who had scabies at baseline, a second
228 dose of the medication that had been provided at baseline was distributed by study staff
229 7 at spot-check sites; individuals were advised to attend the clinic. We attempted to
230 provide treatment to all class-mates where cases of scabies were found during school
231 visits and to the household of cases of found during either school or household visits.

232

233 Analysis:

234 For clinic-based data we report the absolute number of cases of scabies and the
235 proportion of all skin problems seen that were due to scabies. For the community data
236 we report the prevalence of scabies (with and without secondary bacterial infection), for
237 each school area, and the overall intervention area.

238

239

240 **Results**

241 The population living in the catchment area of the Alinafe Health Centre is estimated at
242 29,780 people (2018 census). Between May 2015 and March 2018, the DerMalawi
243 Project conducted 4 health centre-based clinics at which a total of 4,769 people were
244 seen. The number of people seen increased at each skin visit over the period. The
245 proportion and absolute number of scabies diagnosed increased with 13 (2.8%) cases
246 in 2015, 9 (1.9%) in 2016, 146 (14.5%) in 2017 and 792 (38.7%) in 2018 but there were
247 not significant changes in the proportion of cases of other key conditions such as leprosy,
248 impetigo, tumours or fungal infections (Table 1).

Diagnosis	2015	2016	2017	2018
Scabies	13 (2.9%)	9 (1.2%)	146 (15.2%)	792 (39.2%)
Leprosy	5 (1.1%)	6 (0.8%)	10 (1.0%)	4 (0.2%)
Impetigo	18 (3.9%)	24 (3.1%)	27 (2.8%)	46(2.3%)
Skin ulcer	3 (0.7%)	4(0.5%)	8 (0.8%)	30 (1.5%)
Tumor	16 (3.5%)	28 (3.6%)	40 (4.2%)	33 (1.6%)
Fungal disease	192 (42.1%)	243(31.3%)	334 (34.8%)	536 (26.6%)
Total	456	776	960	2018

249 Table 1: Cases seen during clinic-based activities

250

251 Community visits took place between July 2018 and April 2019. We saw 15,290
252 individuals (51.3% of the population) on our first community visit in July 2018, 16,619
253 individuals (55.8%) on our second community visit in October 2018, and 12,617
254 individuals (42.4%) during our third community visit in April 2019 (Table 2).

255

256

257


		July 2018 (N=15487)	October 2018 (N=16619)	April 2019 (N=12617)
Age Group	0-4yrs	2384 (15.4%)	1894 (11.4%)	2143 (17.0%)
	5-9yrs	3411 (22.0%)	4242 (25.5%)	2626 (20.8%)
	10-14yrs	3994 (25.8%)	5490 (33.0%)	2933 (23.2%)
	15-24yrs	2402 (15.5%)	2259 (13.6%)	2033 (16.1%)
	24-34yrs	1344 (8.7%)	1106 (6.7%)	1120 (8.9%)
	>=35yrs	1952 (12.6%)	1628 (9.8%)	1762 (14.0%)
Gender	Female	8714 (56.3%)	9152 (55.1%)	7246 (57.4%)
	Male	6773 (43.7%)	7467 (44.9%)	5371 (42.6%)
Scabies	Absent	13095 (84.6%)	13764 (82.8%)	12314 (97.6%)
	Present	2392 (15.4%)	2855 (17.2%)	303 (2.4%)
Impetigo	Absent	14455 (93.3%)	15915 (95.8%)	11959 (94.8%)
	Present	1032 (6.7%)	704 (4.2%)	658 (5.2%)

258 Table 2: Individuals seen during community-based activities

259

260 The prevalence of scabies was similar during our first two community visits; 15.4%
 261 (2392) in July 2018 and 17.2% (2855) in October 2018 but only 2.4% in April 2019. All
 262 individuals diagnosed with scabies received treatment with IVM but only 47% of cases
 263 seen in the first community visit, and only 55% of cases seen in during the second
 264 community visit were seen for a second dose of treatment. As well as index cases, 5,204
 265 individuals and 7,888 individuals received treatment as contacts during these visits.
 266 Prevalence of impetigo was 6.7% (1032), 4.2% (704), and 5.2% (658) across the three

267 visits. At each community visit the prevalence of scabies varied markedly between
268 villages (range 5-40%, Figure 1). The prevalence of scabies was highest amongst
269 children under 5 (Table 3) at each visit.



270

Figure 1

271 Figure 1

272

273

274

275

276

277

278

	Visit 1		Visit 2		VISIT 3	
Age Group	Prevalence of Scabies	Prevalence of Impetigo	Prevalence of Scabies	Prevalence of Impetigo	Prevalence of Scabies	Prevalence of Impetigo
0-4	20.6%	10.5%	22.3%	5.6%	4%	6.1%
5-9	15.9%	7.9%	18.2%	5.2%	3.2%	9.2%
10-14	15.8%	7.2%	18.7%	4.7%	2.8%	7.1%
15-24	14.8%	5.2%	15.3%	3.3%	1.3%	2.9%
24-34	13.8%	4.0%	11.3%	1.8%	1%	1.1%
≥35	9.6%	10.5%	10.4%	1.9%	0.9%	0.8%

279 Table 3: Prevalence of scabies and impetigo by age group during each visit

280

281 **Discussion**

282 The DerMalawi project has been working in Malawi since 2015. Over that time we noted
 283 a marked increase in presentations to our service for scabies. When we switched to a
 284 community rather than a clinic-based model, we found an extremely high community
 285 prevalence of scabies of 15%. Over the course of three community outreach activities
 286 the prevalence appeared to markedly decline, but whether this reduction is directly
 287 related to our activities and treatment or not, remains unclear.

288 There is limited data on the prevalence of scabies in much of sub-Saharan Africa
 289 although several recent studies suggest that it is common [19] and no recent data on
 290 scabies in Malawi. The data from the DerMalawi project suggests that scabies is a major
 291 problem in the area. We found especially high prevalences amongst children [20–22]

292 There was no change in scabies prevalence between July 2018 and October 2018
 293 suggesting that at the coverage achieved the treatment of cases and a proportion of
 294 their contacts was inadequate to affect scabies prevalence. This lack of change is likely
 295 due to low population coverage. Whilst we switched from a clinic to a community-based
 296 strategy, we still reached only about 50% of the population of our catchment area. Such

297 low coverage invariably leads to a large number of untreated scabies cases that might
298 act as a reservoir for infection. In addition, most individuals received only a single dose
299 of ivermectin limiting the efficacy of treatment for individual patients. All three visits were
300 conducted during the dry season, so differences in prevalence seem unlikely to be
301 related to seasonality [23]. Unlike research interventions that have been carried out in
302 islands or confined populations and have maintained the effects for years [13], the
303 activities reported here were carried out as part of a long term dermatological assistance
304 programme and the patients in our target area, are surrounded by neighbouring
305 communities with potentially high scabies rates. These surrounding areas therefore
306 serve as a further reservoir from which reintroduction can occur.

307 The markedly reduced prevalence observed in our visit in April 2019 despite low
308 treatment coverage, and in the absence of any effect seen previously, suggests that the
309 observed reduction is unlikely to be due to treatment and more likely reflects changes in
310 the population assessed at each time point. In keeping with this there were differences
311 in both the demographic structure of the population seen in our final community visit and
312 in the number of people seen at each screening site across each of our visits. We noted
313 that in the final visit fewer people were able to enter the study because they said they
314 were not affected and refused to be examined. What they find most difficult is getting
315 undressed, and they refused to be examined arguing that they did not notice any itching
316 or skin lesions. For these reasons it seems likely that the reduction seen is most likely
317 a reflection of sampling bias not a true difference.

318 Scabies remains as an unresolved matter for global health, continues to be widespread
319 and is responsible for intense suffering, health and social complications. New drugs,
320 dissemination models and treatment and preventive strategies are needed to achieve
321 better results. Targets for the establishment of scabies control programmes have been
322 included in the new WHO NTD Roadmap 2021-2030 and our data suggests such a
323 programme should be considered in Malawi alongside other national NTD programmes.

324

325

326

327

328 **References**

- 329 1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global,
330 regional, and national incidence, prevalence, and years lived with disability for 310
331 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of
332 Disease Study 2015. *Lancet Lond Engl*. 2016 08;388(10053):1545–602.
- 333 2. Chosidow O. Clinical practices. Scabies. *N Engl J Med*. 2006 Apr
334 20;354(16):1718–27.
- 335 3. Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and
336 topical permethrin cream in the treatment of scabies. *J Am Acad Dermatol*. 2000
337 Feb;42(2 Pt 1):236–40.
- 338 4. Wong L-C, Amega B, Barker R, Connors C, Dulla ME, Ninnal A, et al. Factors
339 supporting sustainability of a community-based scabies control program. *Australas
340 J Dermatol*. 2002 Nov;43(4):274–7.
- 341 5. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al.
342 Mass Drug Administration for Scabies Control in a Population with Endemic
343 Disease. *N Engl J Med*. 2015 Dec 10;373(24):2305–13.
- 344 6. Ly F, Caumes E, Ndaw CAT, Ndiaye B, Mahé A. Ivermectin versus benzyl
345 benzoate applied once or twice to treat human scabies in Dakar, Senegal: a
346 randomized controlled trial. *Bull World Health Organ*. 2009 Jun;87(6):424–30.
- 347 7. Hay RJ, Steer AC, Chosidow O, Currie BJ. Scabies: a suitable case for a global
348 control initiative. *Curr Opin Infect Dis*. 2013 Apr;26(2):107–9.
- 349 8. Engelman D, Kiang K, Chosidow O, McCarthy J, Fuller C, Lammie P, et al.
350 Toward the global control of human scabies: introducing the International Alliance
351 for the Control of Scabies. *PLoS Negl Trop Dis*. 2013;7(8):e2167.
- 352 9. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. *N Engl J Med*.
353 2010 Feb 25;362(8):717–25.
- 354 10. Mounsey KE, McCarthy JS. Treatment and control of scabies. *Curr Opin Infect
355 Dis*. 2013 Apr;26(2):133–9.
- 356 11. La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, Andrews R.
357 Community management of endemic scabies in remote aboriginal communities of
358 northern Australia: low treatment uptake and high ongoing acquisition. *PLoS Negl
359 Trop Dis*. 2009 May 26;3(5):e444.
- 360 12. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C, et al. Control of
361 scabies, skin sores and haematuria in children in the Solomon Islands: another role
362 for ivermectin. *Bull World Health Organ*. 2005 Jan;83(1):34–42.
- 363 13. Marks M, Romani L, Sokana O, Neko L, Harrington R, Nasi T, et al. Prevalence of
364 scabies and impetigo three years after mass drug administration with ivermectin
365 and azithromycin. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2019 May 25;

- 366 14. Kearns TM, Speare R, Cheng AC, McCarthy J, Carapetis JR, Holt DC, et al.
367 Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a
368 Remote Australian Aboriginal Community. *PLoS Negl Trop Dis*. 2015
369 Oct;9(10):e0004151.
- 370 15. Taplin D, Porcelain SL, Meinking TL, Athey RL, Chen JA, Castellero PM, et al.
371 Community control of scabies: a model based on use of permethrin cream. *Lancet*
372 *Lond Engl*. 1991 Apr 27;337(8748):1016–8.
- 373 16. Evans DS, Alphonsus K, Umaru J, Eigege A, Miri E, Mafuyai H, et al. Status of
374 Onchocerciasis transmission after more than a decade of mass drug administration
375 for onchocerciasis and lymphatic filariasis elimination in central Nigeria:
376 challenges in coordinating the stop MDA decision. *PLoS Negl Trop Dis*. 2014
377 Sep;8(9):e31113.
- 378 17. Mohammed KA, Deb RM, Stanton MC, Molyneux DH. Soil transmitted helminths
379 and scabies in Zanzibar, Tanzania following mass drug administration for
380 lymphatic filariasis--a rapid assessment methodology to assess impact. *Parasit*
381 *Vectors*. 2012 Dec 21;5:299.
- 382 18. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al.
383 Mass Drug Administration for Scabies Control in a Population with Endemic
384 Disease. *N Engl J Med*. 2015 Dec 10;373(24):2305–13.
- 385 19. Azene AG, Aragaw AM, Wassie GT. Prevalence and associated factors of scabies
386 in Ethiopia: systematic review and Meta-analysis. *BMC Infect Dis* [Internet].
387 2020;20(1). Available from: <https://dx.doi.org/10.1186/s12879-020-05106-3>
- 388 20. Engelman D, Steer AC. Control Strategies for Scabies. *Trop Med Infect Dis*. 2018
389 Sep 5;3(3).
- 390 21. Mason DS, Marks M, Sokana O, Solomon AW, Mabey DC, Romani L, et al. The
391 Prevalence of Scabies and Impetigo in the Solomon Islands: A Population-Based
392 Survey. Vinetz JM, editor. *PLoS Negl Trop Dis*. 2016 Jun 27;10(6):e0004803.
- 393 22. Tikoduadua L, Kama M, Romani L, Steer AC, Tuicakau M, Whitfeld MJ, et al.
394 The Epidemiology of Scabies and Impetigo in Relation to Demographic and
395 Residential Characteristics: Baseline Findings from the Skin Health Intervention
396 Fiji Trial. *Am J Trop Med Hyg*. 2017 Sep 7;97(3):845–50.
- 397 23. Armitage EP, Senghore E, Darboe S, Barry M, Camara J, Bah S, et al. High
398 burden and seasonal variation of paediatric scabies and pyoderma prevalence in
399 The Gambia: A cross-sectional study. Taylan Ozkan A, editor. *PLoS Negl Trop*
400 *Dis*. 2019 Oct 14;13(10):e0007801.

401

402

403

404

405 **Acknowledgments.**

406 We are extremely grateful to the Missionary Community San Paul the apostle MCSPA
407 for providing accommodation and support for the DerMalawi project, especially Mr. Brian
408 Odhiambo who supports all the dermatological work carried out by the DerMalawi project
409 and F. Manuel Hernandez, head of the parish. We are also extremely grateful to all the
410 members of the community and community leaders for their participation and support of
411 the DerMalawi project over many years.